Patents Assigned to GlaxoSmithKline
  • Amino quinazolines as kinase inhibitors
    Patent number: 10717711
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 21, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam K. Charnley, Xiaoyang Dong
  • ADENINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF ALLERGIC DISEASES OR OTHER INFLAMMATORY CONDITIONS
    Publication number: 20200223849
    Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n-moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 16, 2020
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Helene G. BAZIN-LEE, Yufeng LI
  • Chemical compounds
    Patent number: 10710963
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
    Patent number: 10702521
    Abstract: The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: July 7, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Katherine Louisa Widdowson
  • Methods for inducing an immune response
    Patent number: 10688168
    Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an M72 related antigen and wherein a subsequent administration is delayed.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: June 23, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: William Ripley Ballou, Jr., Marie-Ange Demoitie, Marie-Noelle Renelle Donner, Nadia Ouaked, Stephane Theophile Temmerman
  • Compounds for use in antibacterial applications
    Patent number: 10683307
    Abstract: The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: June 16, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Haifeng Cui, Alan Hennessy, Qi Jin, Timothy James Miles, Stephen Frederick Moss, Neil David Pearson
  • Targeted protein degradation
    Patent number: 10683360
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: June 16, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
  • Crystalline hydrate of the compound (2S,3R)-isopropyl 2-(((2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[D]imidazol-5- yl)methyl)amino)-3-hydroxybutanoate edisylate
    Patent number: 10676466
    Abstract: The present invention relates to a crystalline hydrate of the compound (2S,3R)-isopropyl 2-(((2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-5-yl)methyl)amino)-3-hydroxybutanoate edisylate and to its use in the treatment of various disorders for which a BET inhibitor is indicated, in particular inflammatory and autoimmune diseases, and cancers. Processes for the manufacture of this crystalline form and pharmaceutical compositions comprising the crystalline form are also disclosed and form part of the present invention.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: June 9, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Nicholas Paul Henley
  • Conjugation process
    Patent number: 10669318
    Abstract: The present invention relates to a process for conjugation of an antigen.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: June 2, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
  • PRMT5 inhibitors and uses thereof
    Patent number: 10653693
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 19, 2020
    Assignees: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash
  • CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES
    Publication number: 20200149069
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: January 24, 2020
    Publication date: May 14, 2020
    Applicants: The Government of the United States of America as Represented by the Secretary of the Department of, GlaxoSmithKline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Vaccine
    Patent number: 10646564
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 12, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • NON-CROSS-LINKED ACELLULAR PERTUSSIS ANTIGENS FOR USE IN COMBINATION VACCINES
    Publication number: 20200138927
    Abstract: The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 7, 2020
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Lorenzo TARLI, Mario CONTORNI, Alessandro BARTALESI
  • Device
    Patent number: 10631623
    Abstract: A toothbrush head having a bristle surface with tufts of bristles extending therefrom comprising: first tufts of a mixture of co-extruded bristles and unitary bristles located adjacent to the distal end of the bristle surface; second tufts comprising a mixture of co-extruded bristles and unitary bristles located adjacent to the proximal end of the bristle surface; third tufts comprising tapered bristles located adjacent to the widthways opposite sides of the bristle surface; and fourth tufts comprising a mixture of co-extruded bristles and tapered bristles longer than the co-extruded bristles located as a cluster of fourth tufts widthways between the third tufts and longitudinally between the first and second tufts.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: April 28, 2020
    Assignee: GlaxoSmithKline Consumer Healthcare GmbH and Co. KG
    Inventor: Hans Kraemer
  • Antituberculosis agent
    Patent number: 10624893
    Abstract: The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 21, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Lluis Ballell Pages, David Barros Aguirre, Robert H. Bates, Julia Castro Pichel, Jorge Esquivias Provencio, Kevin Pethe
  • Nrf2 regulators
    Patent number: 10604509
    Abstract: Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 31, 2020
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: Jeffrey K. Kerns, James Callahan, Thomas Daniel Heightman, Alison Jo-Anne Woolford, Ami Lakdawala Shah, Roderick S. Davis, David Norton, Jeffrey Charles Boehm, Nicole Cathleen Goodwin
  • Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N?-(3-Fluoro-2-methylphenyl)urea
    Patent number: 10604485
    Abstract: A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N?-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 31, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Francis Dominic Sanderson, Sarah Mary Vallance
  • Prodrug of 1,1?-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
    Patent number: 10597385
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: March 24, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • TRPV4 antagonists
    Patent number: 10590077
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian W. Budzik, Brian Griffin Lawhorn, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, David J. Behm
  • TRPV4 antagonists
    Patent number: 10588891
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas